stonks4u
Sign up free
OABI logo

OABI OmniAb, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$3.38
-0.05 (-1.46%)

OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capabilit…

Market Cap: $490.01Mwww.omniab.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 17Aug 17

Quote

Day Range
$3.31 – $3.45
52-Week Range
$1.30 – $3.63
Volume
$554.4K
Market Cap
$490.01M
50-Day Avg
$2.35
200-Day Avg
$1.94
Prev Close
$3.43
Open
$3.35

Valuation & Ratios

P/E Ratio
-3.25
EPS
$-0.57
P/B Ratio
0.79
P/S Ratio
11.26
Debt/Equity
0.08
Current Ratio
4.02
Dividend Yield
+0.0%
Gross Margin
-18.2%

Returns & Efficiency

Return on Equity
-24.3%
Return on Assets
-21.5%
FCF Yield
-17.6%
EV/EBITDA
-4.60

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$18.67M$-64.78M$-0.57
2024$26.39M$-62.03M$-0.61
2023$34.16M$-50.62M$-0.51
2022$59.08M$-22.33M$-0.26
2021$34.75M$-27.04M$-0.24

Social Signal Score

51
5d
51
2 mentions
—
30d
51
2 mentions
—
60d
51
2 mentions
—
90d
51
2 mentions
—
news: 2

Earnings

Tue, Nov 3(in 3 months)

Consensus estimate $-0.12 per share

4of 7 quarters beat consensus

Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 6$-0.05 vs $-0.12beat
  • Thu, May 7$-0.06 vs $-0.10beat
  • Wed, Mar 4$-0.11 vs $-0.08miss
  • Tue, Nov 4$-0.14 vs $-0.14miss
  • Wed, Aug 6$-0.15 vs $-0.14miss
  • Thu, May 8$-0.17 vs $-0.17beat

Estimates and results for OABI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by OABI officers and directors.

Bought
$108k

2 trades

Sold
$283k

12 trades

  • Foehr Matthew Wsold
    director, officer: President and CEO·19,244 @ $1.49·$29k·Apr 7, 2026·filing
  • Gustafson Kurt Asold
    Executive VP, Finance and CFO·6,913 @ $1.49·$10k·Apr 7, 2026·filing
  • Berkman Charles Ssold
    Chief Legal Officer·7,157 @ $1.49·$11k·Apr 7, 2026·filing
  • Berkman Charles Ssold
    Chief Legal Officer·9,673 @ $1.71·$17k·Feb 18, 2026·filing
  • Gustafson Kurt Asold
    Executive VP, Finance and CFO·9,301 @ $1.71·$16k·Feb 18, 2026·filing
  • Foehr Matthew Wsold
    director, officer: President and CEO·30,843 @ $1.71·$53k·Feb 18, 2026·filing
  • Foehr Matthew Wsold
    director, officer: President and CEO·20,754 @ $1.70·$35k·Feb 17, 2026·filing
  • Gustafson Kurt Asold
    Executive VP, Finance and CFO·6,828 @ $1.70·$12k·Feb 17, 2026·filing

86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

OABIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (2)

  • Newsbusinesswire.com·6h ago·Neutral

    OmniAb Raises 2026 Financial Guidance EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today raised its 2026 cash and cash equivalents financial guidance following recent technology licensing activity. “Recent business development and licensing activity has enabled us to again raise our 2026 financial guidance and significantly increase our cash outlo…

    View source ↗
  • Newsbusinesswire.com·6h ago·Neutral

    OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages OmniAb's technology platform and experti…

    View source ↗